Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

23.58B

Market cap23.58B

Price-Earnings ratio

16.69

Price-Earnings ratio16.69

Dividend yield

—

Dividend yield—

Average volume

1.99M

Average volume1.99M

High today

—

High today—

Low today

—

Low today—

Open price

$117.53

Open price$117.53

Volume

0.00

Volume0.00

52 Week high

$118.69

52 Week high$118.69

52 Week low

$67.06

52 Week low$67.06

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $118.05. The company's market cap stands at 23.58B, with a P/E ratio of 16.69.

On 2026-07-08, Incyte(INCY) shares started trading at $117.53, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.99M.

The stock's 52-week range extends from a low of $67.06 to a high of $118.69.

INCY News

Investor's Business Daily 14h

Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily

...

TipRanks 1d

Incyte price target raised to $99 from $95 at RBC Capital

RBC Capital raised the firm’s price target on Incyte (INCY) to $99 from $95 and keeps a Sector Perform rating on the shares as part of a broader research note p...

TipRanks 2d

Incyte Acquires Vega Therapeutics, Expands Hematology Pipeline

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Analyst ratings

55%

of 29 ratings

Buy

41.4%

Hold

55.2%

Sell

3.4%

More INCY News

TipRanks 2d

Incyte completes acquisition of Vega Therapeutics

Incyte (INCY) completed its acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics. The acquisition adds VGA039, a novel monoclonal an...

Simply Wall St 3d

Incyte On Opzelura Progress And Strong Revenue Has Valuation Back In Focus

Incyte (INCY) has been in focus after a series of events, including a favorable US$246 million Medicaid settlement tied to Opzelura and a positive European opin...

Simply Wall St 6d

How Investors May Respond To Incyte EMA Backing Opzelura For Moderate Atopic Dermatitis

In late June 2026, Incyte announced that the European Medicines Agency’s CHMP issued a positive opinion recommending approval of Opzelura (ruxolitinib) cream fo...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.